California Healthcare Institute to Host Forum on Molecular Diagnostics Regulation and Reimbursement Keeping Pace With Technology
September 15, 2008
San Diego, Sept. 17, 2008:
WHO: California Healthcare Institute (CHI) and national experts in the molecular and in vitro diagnostics (IVD) industry. WHAT: Keeping Pace with Technology: Molecular Diagnostics Regulation and Reimbursement WHEN: 11:30 a.m. to 6:00 p.m., Wednesday, September 17 WHERE: Gen-Probe Incorporated 10210 Genetic Center Drive San Diego, Calif. 92121 DETAILS: A panel of national experts will discuss how the IVD industry has evolved and expanded our knowledge of the molecular base of cancer and other chronic diseases, and how the federal and state government regulatory and reimbursement agencies are slowing down progress. SPEAKERS: Mari Baker, president and chief executive officer, Navigenics, Inc.; Jeff Bush, director of corporate reimbursement, BD; Robert DiTullio, vice president of regulatory affairs and quality, ProteoGenix, Inc.; David Gollaher, Ph.D., president and CEO, CHI; Alberto Gutierrez, Ph.D., deputy director, Office of In Vitro Diagnostic Device (OIVD) Safety and Evaluation, Center for Devices and Radiological Health (CDRH), FDA; Sheri Hall, vice president of regulatory affairs and quality, BD; Richard Jove, Ph.D.; director, Beckman Research Institute, City of Hope; Hank Nordhoff, chairman and CEO, Gen-Probe Incorporated; Hakan Sakul, Ph.D.; senior director and global head of diagnostics, Pfizer Global Research and Development; Patrick Terry, co-founder and director, Consumer Advocacy and Governmental Affairs, Genomic Health; and Tim Wolleager, managing director, Sanderling Ventures. ATTENDEES: Representatives from the IVD and molecular industry.
Topics: Health Medical Pharma, Navigenics, David Gollaher, California Healthcare Institute, Business Finance